These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A meta-analysis of HIF-1α and esophageal squamous cell carcinoma (ESCC) risk.
    Author: Sun G, Hu W, Lu Y, Wang Y.
    Journal: Pathol Oncol Res; 2013 Oct; 19(4):685-93. PubMed ID: 23658132.
    Abstract:
    To investigate the correlation of hypoxia-inducible factor-1α (HIF-1α) expression with clinical prognosis and efficacy of radiochemotherapy in esophageal squamous cell carcinoma (ESCC). Studies assessing the clinical or prognostic significance of HIF-1α expression in ESCC published prior to December 2011 were selected by searching PubMed, EMBASE, Cochrane Library, and (China National Knowledge Infrastructure) CNKI. A meta-analysis was performed to clarify the impact of HIF-1α expression on clinicopathological parameters or survival in ESCC. A total of 16 studies met the inclusion criteria, which included 1261 patients with ESCC. Accordingly, the level of HIF-1α expression in esophageal tissues of patients with ESCC was significantly higher than that in normal patients (odds ratio, OR = 33.111, 95 % confidence interval, CI = 11.912-92.040). The expression of HIF-1α correlated with the depth of invasion (OR = 1.701, 95 % CI = 1.076-4.705), clinical TNM stage (OR = 2.160, 95%CI = 1.516-3.077), as well as lymph node metastasis (OR = 2.393, 95 % CI = 1.319-4.344), regardless of differentiation grading (OR = 1.185, 95 % CI = 0.859-1.635). Furthermore, there was a significant association of increased HIF-1α expression with poorer radiochemotherapy outcomes, 2-year overall survival (OR = 0.219, 95 % CI = 0.104-0.461) and survival (OR = 0.320, 95 % CI = 0.115-0.887, P < 0.05) in patients with ESCC. In addition, HIF-1α expression correlated with VEGF expression in the ESCCs (OR = 4.635, 95%CI = 2.591-8.292). Increased expression of HIF-1α plays an important role in the malignant biology of ESCC resulting in significantly poorer radiochemotherapy outcomes and 2-year overall survival. HIF-1α expression may be a prognostic factor, as well as a potential target for therapy in patients with ESCC.
    [Abstract] [Full Text] [Related] [New Search]